HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Origins Appeals To NARB Following Case Over Plantscription Claims

This article was originally published in The Rose Sheet

Executive Summary

The Estee Lauder Companies’ Origins unit is appealing to NARB after NAD advised the firm to drop or modify claims comparing its Plantscription products to anti-aging prescription cream Renova.

You may also be interested in...

NARB Tells Origins To Drop Comparison To Rx Anti-Wrinkle Products

The National Advertising Review Board upholds a NAD ruling that the brand should discontinue claims comparing its Plantscription anti-aging serum to anti-wrinkle prescription products. NARB reversed several other NAD decisions on certain claims for the same product.

The Estee Lauder Companies Hails Return Of Luxury Shoppers In U.S.

The return of the luxury shopper in the U.S. and the strength of the travel retail market provided a significant boost to The Estee Lauder Companies' sales and earnings in the fiscal third quarter, the firm reported during a May 5 earnings call.

NAD Takes Issue With University Medical WrinkleFree Claims...Again

Performance claims from University Medical Pharmaceuticals touting the quick-acting effect of its WrinkleFree Eyes and comparing the product to Botox should be discontinued, the National Advertising Division says


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts